IMA · Insider Trading
ImageneBio, Inc. Common Stock
Every open-market purchase and sale reported by IMA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-17 | Yanina Grant-Huerta | Chief Financial Officer | A | +104,000 | — |
| 2026-08-17 | Kristin Yarema | Chief Executive Officer | A | +254,800 | — |
| 2026-07-28 | Kristin Yarema | Chief Executive Officer | MIXED | +153,505 | — |
| 2026-07-20 | Robert B Lally | Principal Accounting Officer | Sell | −3,196 | −$17.33K |
| 2026-06-18 | Joseph P Slattery | Director | A | +15,600 deriv. | — |
| 2026-06-18 | Otello Stampacchia | Director | A | +15,600 deriv. | — |
| 2026-06-18 | David P Bonita | Director | A | +15,600 deriv. | — |
| 2026-06-18 | Jonathan Jian Wang | Director | A | +15,600 deriv. | — |
| 2026-04-16 | OrbiMed Genesis GP LLC | Director | Buy | — | — |
| 2026-04-16 | David P Bonita | Director | Buy | — | — |
| 2026-03-18 | Kristin Yarema | Chief Executive Officer | A | +85,400 | — |
| 2026-01-02 | Erin Butler | Principal Accounting Officer | A | +22,500 | — |
| 2025-12-29 | Joseph P Slattery | Director | Buy | +16,000 | +$95.84K |
| 2025-12-22 | Joseph P Slattery | Director | A | +31,200 deriv. | — |
| 2025-12-22 | Stephen Hui Wang | Director | A | +31,200 deriv. | — |
| 2025-12-22 | Jonathan Jian Wang | Director | A | +31,200 deriv. | — |
| 2025-10-10 | Stephen Hui Wang | Director | A | +250,721 | — |
| 2025-08-15 | Jonathan Jian Wang | Director | A | +1,115,005 | — |
| 2025-08-07 | Yufang Lu | Chief Medical Officer | A | +76,289 deriv. | — |
| 2025-07-30 | Otello Stampacchia | Director | MIXED | +267,935 | +$8.00M |
| 2025-07-30 | David P Bonita | Director | MIXED | +83,990 | +$2.50M |
| 2025-07-30 | Kristin Yarema | Chief Executive Officer | A | +614,020 deriv. | — |
| 2025-07-30 | OrbiMed Genesis GP LLC | Director | A | +250,833 | +$624.57K |
| 2025-07-29 | Erin Butler | Principal Accounting Officer | A | +3,051 | — |
| 2025-07-29 | Jotin Marango | Chief Financial Officer | MIXED | +11,146 | −$79.45K |
| 2010-07-02 | Gordon Norman | Chief Innovation Officer | M | +15,000 deriv. | — |
| 2010-07-02 | Thomas Underwood | CEO, Alere Health LLC | M | +25,000 deriv. | — |
| 2010-06-21 | Emanuel Hart | VP, Lat. Am., Africa & Russia | MIXED | +2,162 | +$26.48K |
| 2010-06-08 | John F Levy | Director | M | +391 | +$1.72K |
| 2010-05-19 | Paul T Hempel | Sr VP, LD & Legal Affairs | MIXED | +1,555 | −$23.60K |
| 2010-03-02 | David Scott | Chief Technical Officer | A | +90,000 deriv. | — |
| 2010-03-02 | Jerome F McAleer | VP, Research & Development | A | +75,000 deriv. | — |
| 2010-03-02 | Ron Zwanziger | Chairman, CEO & President | A | +250,000 deriv. | — |
| 2010-02-23 | Peter Townsend | Director | MIXED | — | −$94.75K |
| 2010-01-05 | David Scott | Chief Technical Officer | A | +90,000 deriv. | — |
| 2010-01-05 | Jerome F McAleer | VP, Research & Development | A | +75,000 deriv. | — |
| 2010-01-05 | Ron Zwanziger | Chairman, CEO & President | A | +250,000 deriv. | — |
| 2009-11-02 | Ellen Chiniara | General Counsel and Asst. Sec. | M | +5,000 deriv. | — |
| 2009-11-02 | Emanuel Hart | VP, Lat. Am., Africa & Russia | M | +5,000 deriv. | — |
| 2009-11-02 | Dave Teitel | Chief Financial Officer | M | +10,000 deriv. | — |
| 2009-11-02 | Jon Russell | VP, Finance | M | +5,000 deriv. | — |
| 2009-09-10 | Paul T Hempel | Sr VP, LD & Legal Affairs | M | +600 | +$822 |
| 2009-09-10 | John F Levy | Director | M | +5,184 | +$7.10K |
| 2009-07-02 | Ellen Chiniara | General Counsel and Asst. Sec. | M | +8,331 deriv. | — |
| 2009-07-02 | Hilde Eylenbosch | President,Consumer Diagnostics | M | +9,227 deriv. | — |
| 2009-07-02 | Paul T Hempel | Sr VP, LD & Legal Affairs | M | +5,676 deriv. | — |
| 2009-07-02 | John Yonkin | President, North America | M | +14,930 deriv. | — |
| 2009-07-02 | Jon Russell | VP, Finance | M | +3,581 deriv. | — |
| 2009-07-02 | Ronald D Geraty | CEO, Alere Medical, Inc. | M | +36,069 deriv. | — |
| 2009-07-02 | Michael K Bresson | VP, Mergers and Acquisitions | M | +2,499 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Jonathan Jian Wang | Director | 1,115,005 | $4.52M |
| David P Bonita | Director | 753,441 | $3.05M |
| OrbiMed Genesis GP LLC | Director | 753,062 | $3.05M |
| Kristin Yarema | Chief Executive Officer | 493,705 | $2.00M |
| Otello Stampacchia | Director | 455,361 | $1.84M |
| Yanina Grant-Huerta | Chief Financial Officer | 65,000 | $263.25K |
| Robert B Lally | Principal Accounting Officer | 55,582 | $225.11K |
| Erin Butler | Principal Accounting Officer | 25,551 | $103.48K |
| Joseph P Slattery | Director | 16,000 | $64.80K |
| Stephen Hui Wang | Director | 12,535 | $50.77K |
| Jotin Marango | Chief Financial Officer | 11,146 | $45.14K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the IMA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.